{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:59:10Z","timestamp":1755223150617,"version":"3.43.0"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Dose adjustments of Day 11 Methotrexate (MTx) for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation (HCT) are common due to mucositis, renal injury, or other reasons. The impact of omitting or adjusting doses of MTx in the era of ATG\u2010based GVHD prophylaxis remains unexplored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed the outcomes of all adult patients undergoing allogeneic HCT who received ATG\u2010based GVHD prophylaxis at The Ottawa Hospital from January 2019 to December 2022. We compared outcomes of patients having only Day 11 MTx dose reductions due to mucositis(MTxRD group) with patients receiving full dose MTx on all 4\u2009days (MTxFD group). The impact of Day 11 MTx dose reduction on outcomes were assessed using Kaplan\u2013Meier analyses and log rank test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three hundred and four patients (median age 58 [17\u201374] years; 64% male) underwent allogeneic HCT during the study period. Baseline characteristics were similar between the MTxRD group (<jats:italic>n<\/jats:italic>\u2009=\u200969) and MTxFD group (<jats:italic>n<\/jats:italic>\u2009=\u2009199) except for an increased proportion of MAC regimens in MTxRD group. The incidence of severe aGVHD (7.2% vs. 7.5%; <jats:italic>p<\/jats:italic>\u2009=\u20090.96) and chronic GVHD (15.9% vs. 15.6%; <jats:italic>p<\/jats:italic>\u2009=\u20090.89) were not different between the two groups. The 2\u2010year OS (59% vs. 69.8%; <jats:italic>p<\/jats:italic>\u2009=\u20090.11), GRFS (42.4% vs. 47.6%; <jats:italic>p<\/jats:italic>\u2009=\u20090.32), NRM (17.7% vs. 12.2%; <jats:italic>p<\/jats:italic>\u2009=\u20090.45) or relapse\/progression (CIR 27.4 vs. 26.6%; <jats:italic>p<\/jats:italic>\u2009=\u20090.55) were also similar between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In patients receiving ATG\u2010based GVHD prophylaxis regimens, there were similar GVHD and survival outcomes in patients who received no or reduced D11 MTx when compared to full dose MTx. Dose adjustments of D11 MTx due to mucositis appear to be safe in the era of ATG\u2010based GVHD prophylaxis regimens.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14380","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T03:20:04Z","timestamp":1736133604000},"page":"785-792","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Day 11 Methotrexate Dose Adjustments due to Mucositis on the Outcomes Following Allogeneic Stem Cell Transplant in the Setting of Anti Thymocyte Globulin (<scp>ATG<\/scp>) Based <scp>GVHD<\/scp> Prophylaxis"],"prefix":"10.1111","volume":"114","author":[{"given":"Vinita","family":"Dhir","sequence":"first","affiliation":[{"name":"Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital University of Ottawa  Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connor","family":"Prince","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital University of Ottawa  Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Allan","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital University of Ottawa  Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold","family":"Atkins","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital University of Ottawa  Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Bredeson","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital University of Ottawa  Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8394-0855","authenticated-orcid":false,"given":"Natasha","family":"Kekre","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital University of Ottawa  Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kennah","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital University of Ottawa  Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Masurekar","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital University of Ottawa  Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2333-4081","authenticated-orcid":false,"given":"Ram","family":"Vasudevan Nampoothiri","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital University of Ottawa  Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.605726"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.08.029"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.228"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.0902"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000030"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34442-y"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14274"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00462-3"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70225-6"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.6.1729.1729"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.08.018"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.02.006"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703616"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.70"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01496-3"},{"issue":"3","key":"e_1_2_9_17_1","first-page":"397","article-title":"Addition of Low\u2010Dose Folinic Acid to a Methotrexate\/Cyclosporin A Regimen for Prevention of Acute Graft\u2010Versus\u2010Host Disease","volume":"14","author":"Russell J. A.","year":"1994","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_9_18_1","unstructured":"\u201cCancer Care Ontario \u2010 Product Monograph for Methotrexate \u201dhttps:\/\/www.cancercareontario.ca\/en\/drugformulary\/drugs\/monograph\/44166."},{"key":"e_1_2_9_19_1","unstructured":"\u201cAlberta BMT Standard Practice Manual: Albreta Health Science Cancer Care Alberta\u201d(2023)."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198603203141201"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.762978"},{"issue":"6","key":"e_1_2_9_22_1","first-page":"755","article-title":"Omission of Day 11 Methotrexate Does Not Appear to Influence the Incidence of Moderate to Severe Acute Graft\u2010Versus\u2010Host Disease, Chronic Graft\u2010Versus\u2010Host Disease, Relapse Rate or Survival After HLA\u2010Identical Sibling Bone Marrow Transplantation","volume":"16","author":"Atkinson K.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.128"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705488"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2032036"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.7.1838.1838"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.11.006"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.349"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.08.007"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T12:08:33Z","timestamp":1754914113000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/ejh.14380"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14380","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"2024-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}